|
1
|
Liu X, Cheng Y, Sheng W, Lu H, Xu Y, Long
Z, Zhu H and Wang Y: Clinicopathologic features and prognostic
factors in alpha-fetoprotein-producing gastric cancers: Analysis of
104 cases. J Surg Oncol. 102:249–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chun H and Kwon SJ: Clinicopathological
characteristics of alpha-fetoprotein-producing gastric cancer. J
Gastric Cancer. 11:23–30. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ooi A, Nakanishi I, Sakamoto N, Tsukada Y,
Takahashi Y, Minamoto T and Mai M: Alpha-fetoprotein
(AFP)-producing gastric carcinoma. Is it hepatoid differentiation?
Cancer. 65:1741–1747. 1990.PubMed/NCBI
|
|
4
|
Jia Y, Liu D, Xiao D, Ma X, Han S, Zheng
Y, Sun S, Zhang M, Gao H, Cui X and Wang Y: Expression of AFP and
STAT3 is involved in arsenic trioxide-induced apoptosis and
inhibition of proliferation in AFP-producing gastric cancer cells.
PLoS One. 8:e547742013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu DP, He QJ and Liu CG: Correlations
among Helicobacter pylori infection and the expression of
cyclooxygenase-2 and vascular endothelial growth factor in gastric
mucosa with intestinal metaplasia or dysplasia. J Gastroenterol
Hepatol. 25:795–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim T and Yu W: Prognostic value of
preoperative serum alpha- fetoprotein level in resectable gastric
cancer. J Korean Gastric Cancer Assoc. 3:33–37. 2003.(In Korean).
View Article : Google Scholar
|
|
7
|
Lim JH, Lee DH, Shin CM, Kim N, Park YS,
Jung HC and Song IS: Clinicopathological features and surgical
safety of gastric cancer in elderly patients. J Korean Med Sci.
29:1639–1645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sato Y, Nishimaki T, Date K, Shirai Y,
Kurosaki I, Saito Y, Watanabe T and Hatakeyama K: Successful
resection of metachronous liver metastasis from
alpha-fetoprotein-producing gastric cancer: Report of a case.
Surgery Today. 29:1075–1088. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhong DT, Wu RP, Wang XL, Huang XB, Lin
MX, Lan YQ and Chen Q: Combination chemotherapy with S-1 and
oxaliplatin (SOX) as first-line treatment in elderly patients with
advanced gastric cancer. Pathol Oncol Res. 21:867–873. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu GF, Tang D, Li P, Wang S, Xu YX, Long
AH, Zhou NL, Zhang LL, Chen J and Xiang XX: S-1-based combination
therapy vs S-1 monotherapy in advanced gastric cancer: A
meta-analysis. World J Gastroenterol. 20:310–318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi C, Chen Q, Shen S, Wu R, Yang B, Liu Q
and Xu Q: Paclitaxel combined with oxaliplatin as first-line
chemotherapy for locally advanced or metastatic gastric cancer.
Expert Rev Anticancer Ther. 15:595–601. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang L, Yang YI, Qin Q, Zhou A, Zhao J,
Wang J, Shu C, Yuan X and Hu S: Evaluation of the optimal dosage of
S-1 in adjuvant SOX chemotherapy for gastric cancer. Oncol Lett.
9:1451–1457. 2015.PubMed/NCBI
|
|
13
|
Oh SY, Kwon HC, Jeong SH, Joo YT, Lee YJ,
Cho Sh, Kang MH, Go SI, Lee GW, Kim Hg and Kang JH: A phase II
study of S-1 and oxaliplatin (SOx) combination chemotherapy as a
first-line therapy for patients with advanced gastric cancer.
Invest New Drugs. 30:350–356. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu B, Ying J, Luo C, Xu Q, Zhu L and
Zhong H: S-1 combined with oxaliplatin as first line chemotherapy
for Chinese advanced gastric cancer patients.
Hepatogastroenterology. 59:6492012.PubMed/NCBI
|
|
15
|
Nishikawa K, Fujitani K, Inagaki H,
Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu
T, Yoshikawa T, et al: Randomised phase III trial of second-line
irinotecan plus cisplatin versus irinotecan alone in patients with
advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Eur J Cancer. 51:808–816. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feng D, Leong M and Li T, Chen L and Li T:
Surgical outcomes in patients with locally advanced gastric cancer
treated with S-1 and oxaliplatin as neoadjuvant chemotherapy. World
J Surg Oncol. 13:112015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Samaratunga H, Samaratunga D, Dunglison N,
Perry-Keene J, Nicklin J and Delahunt B:
Alpha-fetoprotein-producing carcinoma of the renal pelvis
exhibiting hepatoid and urothelial differentiation. Anticancer Res.
32:4987–4991. 2012.PubMed/NCBI
|
|
21
|
Bourreille J, Metayer P, Sauger F, Matray
F and Fondimare A: Existence of alpha feto protein during
gastric-origin secondary cancer of the liver. Presse Med.
78:1277–1278. 1970.(In French). PubMed/NCBI
|
|
22
|
Lunghi A, Petreni P, Romanelli RG,
Vizzutti F, Marra F, Tarquini R and Laffi G: Aggressive gastric
carcinoma producing alpha-fetoprotein: A case report and review of
the literature. Case Rep Oncol. 7:92–96. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X, Yang M, Gao J, Zhang S and Xi Y:
Clinicopathologic features and prognosis of 51 patients with
α-fetoprotein-producing gastric cancer. Zhonghua Zhong Liu Za Zhi.
37:231–234. 2015.(In Chinese). PubMed/NCBI
|
|
24
|
Yamashita T, Nakane A, Watanabe T, Miyoshi
I and Kasai N: Evidence that alpha-fetoprotein suppresses the
immunological function in transgenic mice. Biochem Biophys Res
Commun. 201:1154–1159. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iida M, Imura J, Furuichi T, Sawada T,
Nagawa H and Fujimori T: Alteration of the AT motif binding
factor-1 expression in alpha-fetoprotein producing gastric cancer:
Is it an event for differentiation and proliferation of the tumors?
Oncol Rep. 11:3–7. 2004.PubMed/NCBI
|
|
26
|
Tiberio GA, Roviello F, Donini A and de
Manzoni G; Italian Research Group for Gastric Cancer, : Hepatic
metastases from gastric cancer: A surgical perspective. World J
Gastroenterol. 21:11489–11492. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kerkar SP, Kemp CD and Avital I: Liver
resections in metastatic gastric cancer. HPB (Oxford). 12:589–596.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu SF, Lu CR, Cheng HD, Xi HQ, Cui JX, Li
JY, Shen WS and Chen L: Comparison of therapeutic efficacy between
gastrectomy with transarterial chemoembolization plus systemic
chemotherapy and systemic chemotherapy alone in gastric cancer with
synchronous liver metastasis. Chin Med J (Engl). 128:2194–2201.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Z, Fan B, Shan F, Tang L, Bu Z, Wu A,
Zhang L, Wu X, Zong X, Li S, et al: Gastrectomy in comprehensive
treatment of advanced gastric cancer with synchronous liver
metastasis: A prospectively comparative study. World J Surg Oncol.
13:2122015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kinoshita T, Kinoshita T, Saiura A, Esaki
M, Sakamoto H and Yamanaka T: Multicentre analysis of long-term
outcome after surgical resection for gastric cancer liver
metastases. Br J Surg. 102:102–107. 2015. View Article : Google Scholar : PubMed/NCBI
|
